DE3247062A1 - Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit - Google Patents

Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit

Info

Publication number
DE3247062A1
DE3247062A1 DE19823247062 DE3247062A DE3247062A1 DE 3247062 A1 DE3247062 A1 DE 3247062A1 DE 19823247062 DE19823247062 DE 19823247062 DE 3247062 A DE3247062 A DE 3247062A DE 3247062 A1 DE3247062 A1 DE 3247062A1
Authority
DE
Germany
Prior art keywords
deferoxamine
disease
acid addition
patients
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19823247062
Other languages
German (de)
English (en)
Other versions
DE3247062C2 (enExample
Inventor
Donald Raymond Prof. Toronto Ontario McLachlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MCLACHLAN DONALD RAYMOND PROF
Original Assignee
MCLACHLAN DONALD RAYMOND PROF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MCLACHLAN DONALD RAYMOND PROF filed Critical MCLACHLAN DONALD RAYMOND PROF
Publication of DE3247062A1 publication Critical patent/DE3247062A1/de
Application granted granted Critical
Publication of DE3247062C2 publication Critical patent/DE3247062C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19823247062 1981-12-21 1982-12-20 Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit Granted DE3247062A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/332,794 US4419365A (en) 1981-12-21 1981-12-21 Method of treating Alzheimer's disease

Publications (2)

Publication Number Publication Date
DE3247062A1 true DE3247062A1 (de) 1983-07-07
DE3247062C2 DE3247062C2 (enExample) 1993-07-01

Family

ID=54774394

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823247062 Granted DE3247062A1 (de) 1981-12-21 1982-12-20 Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit

Country Status (6)

Country Link
US (1) US4419365A (enExample)
JP (1) JPS58121213A (enExample)
BE (1) BE895406A (enExample)
DE (1) DE3247062A1 (enExample)
IT (1) IT1155241B (enExample)
ZA (1) ZA829335B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214101A3 (de) * 1985-09-03 1989-05-31 Ciba-Geigy Ag Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912118A (en) * 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
DE3579164D1 (de) * 1984-12-19 1990-09-13 Ciba Geigy Ag Neue kohlensaeureester.
US5217998A (en) * 1985-07-02 1993-06-08 Biomedical Frontiers, Inc. Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
MX12394A (es) * 1987-07-23 1993-12-01 Ciba Geigy Ag Procedimiento par la obtencion de carbamatos de polietilenglicol.
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US5023784A (en) * 1989-04-06 1991-06-11 Doral Technical Services, Inc. Method for diagnosing serum deficiencies
US5158979A (en) * 1989-04-19 1992-10-27 New York University Method and compositions for treating pneumocystic carini infections
US5268165A (en) * 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
CA2123211C (en) * 1991-11-12 2008-09-16 Colin L. Masters A method for assaying and treating alzheimer's disease
HU214452B (hu) * 1992-06-01 1998-03-30 BIOGAL Gyógyszergyár Rt. Eljárás nagytisztaságú deferoxamin-B-sók előállítására
GB9211779D0 (en) * 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts
TW274630B (enExample) * 1994-01-28 1996-04-21 Wako Zunyaku Kogyo Kk
JPH0925234A (ja) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US6780852B2 (en) 1997-12-09 2004-08-24 Bo E. Hedlund Modified polysaccharides exhibiting altered biological recognition
US20030236224A1 (en) * 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
CA2314716C (en) 1997-12-09 2009-02-03 Biomedical Frontiers, Inc. Modified polysaccharides exhibiting altered biological recognition
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
DE10222561B4 (de) 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
EP2977056B1 (en) 2014-07-11 2018-09-12 Grifols Worldwide Operations Limited Transferrin for use in the treatment of hypoxia inducible factor (hif)-related neurodegenerative disorders
CN112972490B (zh) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1898E (fr) 1903-04-01 1903-11-07 Louis Galland Concasseur à machoires multiples
DE1123436B (de) 1959-09-25 1962-02-08 Ciba Geigy Verfahren zur Herstellung neuer Wuchsstoffe
DE1186076B (de) 1960-10-11 1965-01-28 Ciba Geigy Verfahren zur Gewinnung komplexmetallfreier Ferrioxamine
DK107752C (da) 1960-10-11 1967-07-03 Ciba Geigy Fremgangsmåde til fremstilling af trihydroxamsyrer eller salt eller metalkomplekser deraf.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DRÜCKE, T.: Aluminiumintoxikation bei Dialyse- behandlung, Med. Praxis 80, Nr. 12, 1985, S. 36- 39 *
STROHMEYER, G. und STREMMEL, W.: Therapie der Hämosiderose mit Deferoxamin, DMW 109. Jg., Nr. 44, 1984, S. 1669-1670 *
US-B.: The Merck-Index, Merck + Co, Inc. Rahway, N.J., USA 1976, S. 374 *
US-Z.: ACKRILL, P. et al.: The Lancet, 27.9.1980, Vol. 2, S. 692-693 *
WILHELM, M.: Aluminium und Alzheimer Krankheit, DMW 113. Jg., Nr. 7, 1988, S. 276 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214101A3 (de) * 1985-09-03 1989-05-31 Ciba-Geigy Ag Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria

Also Published As

Publication number Publication date
BE895406A (fr) 1983-06-20
JPS58121213A (ja) 1983-07-19
ZA829335B (en) 1983-09-28
JPH0318602B2 (enExample) 1991-03-13
IT8249698A1 (it) 1984-06-20
IT1155241B (it) 1987-01-21
IT8249698A0 (it) 1982-12-20
US4419365A (en) 1983-12-06
DE3247062C2 (enExample) 1993-07-01

Similar Documents

Publication Publication Date Title
DE3247062C2 (enExample)
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
DE69325393T2 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE3005208A1 (de) Verwendung von acylcarnitin in arzneimitteln zur behandlung von stoerungen im gehirn-metabolismus
DE69129115T2 (de) Neues verfahren zur behandlung von depression
DE69231955T2 (de) Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz
EP0326023B1 (de) Benzamid gegen kognitive Erkrankungen
DE60101309T2 (de) Diacerein zur behandlung von psoriasis
DE3722383A1 (de) Neue verwendung von bromocriptin
DE69731968T2 (de) Isovaleramid zur behandlung von schüttelkrämpfen, epilepsie, kopfschmerzen und spastischer lähmung
DE69333014T2 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
DE3882135T2 (de) Verwendung von melatonin oder seine derivate zur herstellung von arzneimitteln, die gegen alterskrankheiten wirksam sind.
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
EP0575613B1 (de) Verwendung der aminosäure glycin zur herstellung von arzneimitteln mit antistress-, stressschutz- und nootroper wirkung
CH670952A5 (enExample)
EP1834640A2 (de) Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
DE2351345A1 (de) Therapeutische zubereitung
DE68909304T2 (de) Aminosäuren für der Behandung neurodegenerativer Störungen.
DE69904297T2 (de) Neue verwendung von ropivacain zur schmerzbehandlung
DE2125427A1 (de) Therapeutisches Mittel
DD300508A5 (de) Verfahren zur Herstellung eines pharmazentischen präparates
Dallaire et al. Premedication of dogs with acepromazine or pentazocine before euthanasia with carbon monoxide
DE3789173T2 (de) Verwendung von Ketamin zur Herstellung von Arzneimitteln zur Prävention oder Linderung der Effekte von Schlaganfall bei einer Person mit erhöhtem Risiko für Schlaganfall.
DE4122585C2 (de) Verwendung einer Peptidfraktion bei Stoffwechselstörungen mit Gewichtsverlust

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee